GH secretagogue
CJC-1295 with DAC
Dosed once weekly at 1 to 2 mg, which is how it is overwhelmingly run in practice: the albumin binding makes the weekly total the meaningful quantity, and splitting it across the week buys nothing.
Also known as CJC-1295 DAC · DAC:GRF · Drug Affinity Complex GRF · CJC-1295
At a glance
Dose summary
No regulator and no trial set these numbers. They describe what people actually do, recorded so you can see the range rather than guess at it — which is not the same thing as a recommendation.
Reconstitution
What to draw, at the usual vial
A 10 mg vial reconstituted with 2 mL of bacteriostatic water gives 5.00 mg/mL. A typical 1.5 mg dose is 0.300 mL — pull the plunger to 30 units on a U-100 syringe.
Same dose, other vial sizes
| Vial | Water | Concentration | Draw | Units | Doses |
|---|---|---|---|---|---|
| 2 mg | 2 mL | 1.00 mg/mL | 1.500 mL | 150 units | 1 |
| 5 mg | 2 mL | 2.50 mg/mL | 0.600 mL | 60 units | 3 |
| 10 mg | 2 mL | 5.00 mg/mL | 0.300 mL | 30 units | 6 |
The highlighted row is the one quoted above: the smallest listed vial that holds at least four typical doses. Change any of it — a different vial, more or less water, a different dose — on the reconstitution calculator, which draws the syringe to true U-100 graduations.
Mechanism & evidence
What it is, and what is known
Dosed once weekly at 1 to 2 mg, which is how it is overwhelmingly run in practice: the albumin binding makes the weekly total the meaningful quantity, and splitting it across the week buys nothing. A GHRH (1-29) analogue carrying a Drug Affinity Complex maleimide that binds serum albumin, which is the ONLY reason it differs from the no-DAC version: the terminal half-life runs roughly 6 to 8 days instead of minutes, so a single dose produces a sustained rise in GH and IGF-1 rather than a discrete pulse.
Phase 1 human dosing studies used single subcutaneous doses of about 30 to 250 mcg/kg. Development was discontinued and it is NOT approved by any regulator; consumer supply is research-chemical grade. Because exposure is continuous rather than pulsatile, it is the less physiologic of the two CJC-1295 forms and carries more of the water-retention and glucose signal.
The caveat
Phase 1 dosing studies only; development was discontinued.Tolerability
Reported side effects
- Water retention and puffiness, more pronounced than with short-acting GHRHs
- Injection site redness or swelling
- Head rush, flushing or transient dizziness
- Tingling or numbness in the hands, which can reflect carpal tunnel pressure
- Reduced insulin sensitivity and higher fasting glucose with sustained elevation
- Lethargy or headache, often reported in the first week
Hard stops
Do not use this if
- Pregnancy, possible pregnancy, or breastfeeding
- Active, suspected or recently treated malignancy
- Under 18
These are flags, not a screening. They do not replace a conversation with a clinician who knows your history.
Handling
Storage
Keep it cold, keep it dark, and label the vial with the date you mixed it. Discard anything cloudy or past the window above.
Combinations
Commonly stacked with
Stacking multiplies the side-effect surface and makes it impossible to tell which compound did what. Add one thing at a time.
References
Sources
Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.